First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

Goffin, John R.; Lacchetti, Christina; Ellis, Peter; Ung, Yee C.; Evans, William K.

doi:10.1097/jto.0b013e3181c6f035

Cited by 179 publications

(128 citation statements)

References 78 publications

(131 reference statements)

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…This approach is characterized by appreciable efficacy and acceptable toxicity, and has been suggested as the reference standard therapeutic approach. 30 In the present study, we showed that the viability of 3 NSCLC cell lines was significantly decreased by curcumin and fenretinide combination treatment compared to single agent treatment in a concentration-dependent manner ( Fig. 1 and Fig.…”

Section: Discussionmentioning

confidence: 60%

Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Chen

Wang

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

Curcumin and fenretinide are 2 well-known and promising chemotherapeutic compounds via various molecular mechanisms. However, the anticancer capacity of either curcumin or fenretinide is limited. This prompted us to examine the combined anticancer effects of curcumin and fenretinide. Our results demonstrate for the first time that there is synergistic anticancer effect of combined treatment with these 2 agents, leading to enhanced cytotoxicity and enhanced expression level of pro-apoptotic protein cleaved PARP in non-small cell lung cancer (NSCLC) cells while showed little toxicity to rat cardiomyoblast normal cells. The combination treatment was also demonstrated to inhibit lung carcinoma growth in vivo. Furthermore, we show that fenretinide or the ER stress inhibitor 4-PBA decreased curcumin-induced Glucose-regulated protein 78 (GRP78) upregulation, and produced a similar enhanced cytotoxic effect. In addition, GRP78 knockdown by siRNA also enhanced the cytotoxic effect of curcumin in A549 and H1299 cells. Our findings suggest that the 2 small molecules, when used in combination, can potentially be effective therapeutic agents for treating NSCLC, at least in part, by regulating endoplasmic reticulum (ER) chaperone protein GRP78.Abbreviations: NSCLC, non-small cell lung cancer; GRP78, Glucose-regulated protein 78; ER, endoplasmic reticulum; 4-PBA, 4-phenylbutyrate; LLC, Lewis lung carcinoma KEYWORDS Curcumin; fenretinide; GRP78; non-small cell lung cancer

show abstract

Section: Discussionmentioning

confidence: 60%

Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Chen

Wang

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Cisplatin has less potential to cause alopecia and thrombocytopenia, but it causes greater emesis and renal and ototoxicity. For older patients and those not fit enough for platinum combination therapy, single-agent therapy such as vinorelbine, gemcitabine, or taxanes are offered 7 . Some centres also offer non-platinum-based doublets that have been shown to have similar efficacy in clinical trials, such as gemcitabine-taxane combinations or gemcitabine-vinorelbine 34,35 .…”

Section: Mutation-positive Nsclcmentioning

confidence: 99%

“…Systemic therapy, the mainstay of treatment in advanced nsclc, can improve survival by up to 8-12 months in selected patients and can improve symptom control and quality of life in 60%-70% despite treatment toxicity 4,[6][7][8] .…”

Section: Introductionmentioning

confidence: 99%

Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Leighl

2012

Current Oncology

114

View full text Add to dashboard Cite

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line Curr Oncol, Vol. 19, pp. S52-S58; doi: http://dx.doi.org/10.3747/co.19.1114 ABSTRACT Metastatic non-small-cell lung cancer (nsclc) is the leading cause of cancer mortality in Canada. Although treatment outcomes in advanced disease remain modest, with paradigm shifts in the approach to treatment, they are steadily improving. Customizing treatment based on histology and molecular typing has become the standard of care. EGFR genotyping and pathology subtyping should be considered routine in new diagnoses of metastatic nsclc. Treatment options for those with somatic EGFR activating mutations include gefitinib until progression, followed by standard chemotherapy. For patients with wild-type EGFR, or in patients whose EGFR genotype is unknown, platinum-based chemotherapy remains the firstline standard, with single-agent chemotherapy as an option for older patients and those who are unfit for platinum-doublet therapy. Patients with nonsquamous histology may receive treatment regimens incorporating pemetrexed or bevacizumab. In patients with squamous cell carcinoma, the latter agents should be avoided because of concerns about enhanced toxicity or decreased efficacy. Secondline chemotherapy is offered to a selected subgroup of patients upon progression and may include pemetrexed in non-squamous histology and docetaxel or erlotinib (or both) in all histologies. Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first-and second-line chemotherapy. Maintenance therapy is emerging as a new option for patients, as are targeted therapies for particular molecular subtypes of nsclc, such as crizotinib in tumours harbouring the EML4-ALK gene rearrangement. KEY WORDSMetastatic non-small-cell lung cancer, nsclc, advanced, systemic therapy, chemotherapy INTRODUCTIONAt more than 25,000 new cases, lung cancer remains the most commonly diagnosed cancer among Canadians (excluding non-melanoma skin cancer); it also causes the greatest number of cancer-related deaths (more than 20,000 deaths per year) 1 . As well, more than half the Canadians diagnosed with lung cancer present with metastatic disease. Most lung cancer patients, approximately 85%, have non-small-cell lung cancer (nsclc). Of those, approximately 40%-60% have adenocarcinoma histology; 10%-15%, squamous histology; 5%, neuroendocrine histology; and the rest, "not otherwise specified" 2,3 .Survival is short in the setting of advanced nsclc, a median of 4-6 months, and more than 80% patients have multiple severe cancer-related symptoms 4-6 . Systemic therapy, the mainstay of treatment in advanced nsclc, can improve survival by up to 8-12 months in selected patients and can improve symptom control and quality of life in 60%-70% despite treatment toxicity 4,[6][7][8] .Since the year 2000, exciting developments have occurred in the treatment of lung cancer, resulting in a paradigm shift. The approach to lung cancer h...

show abstract

“…Niezależnie od tego u części chorych uzyskuje się zmniejszenie dolegliwości związanych z nowotworem. Obecnie standardem są dwulekowe schematy z udziałem leków trzeciej generacji w połączeniu z pochodnymi platyny [75,76]. Trzylekowe schematy nie są skuteczniejsze od dwulekowych [77][78][79][80].…”

Section: Chemioterapia I Linii W Zaawansowanym Ndrpunclassified

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Jassem

Biernat

Bryl

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Rak płuca jest w Polsce najczęstszą przyczyną zgonów nowotworowych. Około 85% wszystkich nowotworów płuca stanowi rak niedrobnokomórkowy (NDRP), w którym leki cytotoksyczne i ukierunkowane molekularnie odgrywają coraz większą rolę. W pracy przedstawiono oparte na obecnej wiedzy zalecenia dotyczące stosowania tych metod w praktyce klinicznej u chorych na NDRP oraz na złośliwego międzybłoniaka opłucnej.

show abstract

First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

Abstract: In NSCLC, a combination of a platinum agent plus a new agent continues to be the standard of care. As differences between regimens are small, toxicity and patient preference should help guide regimen choice.

Cited by 179 publications

References 78 publications

Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Contact Info

Product

Resources

About